Linked Life Data

12827614

Source:http://linkedlifedata.com/resource/pubmed/id/12827614

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12827614rdf:typepubmed:Citationlld:pubmed
pubmed-article:12827614lifeskim:mentionsumls-concept:C0040132lld:lifeskim
pubmed-article:12827614lifeskim:mentionsumls-concept:C0007131lld:lifeskim
pubmed-article:12827614lifeskim:mentionsumls-concept:C0033105lld:lifeskim
pubmed-article:12827614lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:12827614lifeskim:mentionsumls-concept:C0040649lld:lifeskim
pubmed-article:12827614lifeskim:mentionsumls-concept:C1519522lld:lifeskim
pubmed-article:12827614lifeskim:mentionsumls-concept:C0021044lld:lifeskim
pubmed-article:12827614lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:12827614lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:12827614lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:12827614lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:12827614pubmed:issue6lld:pubmed
pubmed-article:12827614pubmed:dateCreated2003-6-26lld:pubmed
pubmed-article:12827614pubmed:abstractTextThyroid transcription factor 1 (TTF-1), a homeodomain-containing transcription factor, plays a pivotal role in lung development, cell growth, and differentiation processes. The current literature reports considerable variation in frequency of TTF-1 protein expression in human non-small cell lung cancer (NSCLC). TTF-1 expression has not been extensively investigated as a prognostic marker in NSCLC. To assess the prevalence of TTF-1 expression, and to evaluate its potential role in disease prognosis, 140 stage I-IIIA NSCLCs with long-term follow-up were studied under uniform conditions using high-density tissue microarray (TMA) combined with immunohistochemistry. Patient survival and association of TTF-1 expression with clinicopathologic parameters were analyzed. One hundred twenty-six tumor samples were fully assessable after tissue processing. Sixty-four samples (50.8%) expressed TTF-1 and 62 (49.2%) displayed no expression. TTF-1 expression was significantly (P < 0.001) correlated with histological subtype: 51 adenocarcinomas (AdCs) (51 of 75; 68%) versus 9 squamous cell carcinomas (SCCs) (9 of 43; 21%) were TTF-1 positive. TTF-1 expression, performance status, nodal status, and tumor stage were significantly related to patient survival. In multivariate analysis, positive TTF-1 expression tended to favor a better patient outcome (P = 0.05). Overall, NSCLC patients with positive TTF-1 expression had a median survival of greater than 57.3 months, whereas those with negative expression had a median survival of 39.4 +/- 5.2 months (log-rank test, P = 0.0067). In this study we found that TTF-1 is predominately expressed in adenocarcinoma. The loss of TTF-1 expression was associated with aggressive behavior of NSCLCs. The results from this study strongly indicate that further investigation is warranted to better define the role of TTF-1 as a prognostic factor in this malignancy.lld:pubmed
pubmed-article:12827614pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12827614pubmed:languageenglld:pubmed
pubmed-article:12827614pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12827614pubmed:citationSubsetIMlld:pubmed
pubmed-article:12827614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12827614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12827614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12827614pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12827614pubmed:statusMEDLINElld:pubmed
pubmed-article:12827614pubmed:monthJunlld:pubmed
pubmed-article:12827614pubmed:issn0046-8177lld:pubmed
pubmed-article:12827614pubmed:authorpubmed-author:LiQiangQlld:pubmed
pubmed-article:12827614pubmed:authorpubmed-author:BrooksJohnJlld:pubmed
pubmed-article:12827614pubmed:authorpubmed-author:TanDongfengDlld:pubmed
pubmed-article:12827614pubmed:authorpubmed-author:AndersonTimot...lld:pubmed
pubmed-article:12827614pubmed:authorpubmed-author:WisemanSamSlld:pubmed
pubmed-article:12827614pubmed:authorpubmed-author:SlocumHarry...lld:pubmed
pubmed-article:12827614pubmed:authorpubmed-author:DeebGeorgeGlld:pubmed
pubmed-article:12827614pubmed:authorpubmed-author:RamnathNithyi...lld:pubmed
pubmed-article:12827614pubmed:authorpubmed-author:CheneyRichard...lld:pubmed
pubmed-article:12827614pubmed:authorpubmed-author:LoewenGregory...lld:pubmed
pubmed-article:12827614pubmed:issnTypePrintlld:pubmed
pubmed-article:12827614pubmed:volume34lld:pubmed
pubmed-article:12827614pubmed:ownerNLMlld:pubmed
pubmed-article:12827614pubmed:authorsCompleteYlld:pubmed
pubmed-article:12827614pubmed:pagination597-604lld:pubmed
pubmed-article:12827614pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:meshHeadingpubmed-meshheading:12827614...lld:pubmed
pubmed-article:12827614pubmed:year2003lld:pubmed
pubmed-article:12827614pubmed:articleTitleThyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study.lld:pubmed
pubmed-article:12827614pubmed:affiliationLung Cancer Program, Roswell Park Cancer Institute, State University of New York, Buffalo, USA.lld:pubmed
pubmed-article:12827614pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12827614pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12827614lld:pubmed